Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)
Finasteride Tablet, Film Coated
Product Images NDC 82009-061
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 82009-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)
This appears to be a figure from a medical study evaluating the percent of patients having surgery for BPH (benign prostatic hyperplasia) and the effect of Finasteride compared to a Placebo. The percent of patients having surgery for BPH, including TURP (Transurethral resection of the prostate), is shown in a graph over an observation time of 48 months. The placebo group had 37 events cumulatively, and the finasteride group had 18 events cumulatively. The number at risk per year is also shown for each group.*
Figure3 (Finasteride Fig3)
The text describes a figure showing the percentage of patients who developed acute urinary retention (spontaneous and precipitated) over a period of observation time (in months). The percentage ranges from 0 to 20% and is higher in the placebo group. There is also information on the cumulative number of events and the number at risk for each group at different observation times. Not available.*
Figure4 (Finasteride Fig4)
Figure5 (Finasteride Fig5)
Package Label-principal Display Panel (5 mg (100 Tablets Bottle))
This is a description of a medication called Finasteride, printed on a bottle that contains 500 tablets of 5mg each. The recommended dosage for adults is one tablet per day., and the tablets should be stored at a temperature of 20°C to 25°C in a closed container, away from light. The medication should not be taken by women and children, or handled by women who are pregnant or may potentially become pregnant. The manufacturer is Auwobiodo Banm Finiiad & M, based in Hyderabad, India, and the medication is distributed by Quallent Pharmaceuticals Health LLC, in Grand Cayman, Cayman Islands. The packaging includes a circular that provides additional information on the medication. The text also includes information regarding printing details that will be printed during packing.*
Chemical Structure (Finasteride Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
